← All companies
ELI LILLY & Co
LLY - CIK 0000059478
Market cap$1.070 T
Rank#10
SEC filings989
ELI LILLY & Co trades as LLY and has a market capitalization of $1.070 T, making it the #10 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $65.18B, up 44.7% from the prior year and net income of $20.64B. This page tracks ELI LILLY & Co through 989 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$65.18BFY 2025
Net income (latest FY)$20.64BFY 2025
Operating cash flow (latest FY)$16.81BFY 2025
Total assets (latest FY)$112.48BFY 2025
Net margin31.7%latest FY
Financial performance
Over the last 9 fiscal years ELI LILLY & Co's revenue grew from $18.31B to $65.18B, a compound annual growth rate of 15.1%. Net profit margin expanded from 14.9% to 31.7% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $1.070 T
- Share price (derived)market cap / shares outstanding
- $1136.37
- P/E ratio (trailing FY)
- 51.8
- EPS (diluted)FY 2025
- $22.95
- Shares outstandingas of 2026-04-27
- 0.94B
- Total equityas of 2026-03-31
- $31.20B
- Return on equity
- 66.2%
- Long-term debtas of 2026-03-31
- $39.37B
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| SD | - | 2026-05-11 |
| Prospectus supplement | 424B2 | 2026-05-08 |
Recent press releases
- Single Dose Lillys Pcsk9 Base Editor Verve 102 Reduced Pcsk9 882026-05-25
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia | Eli Lilly and Company
- Results were consistent across both age groups (<65 and ≥65 years), with and without type 2 diabetes, supporting Foundayo as a treatment option across a broad adult population2026-05-22
Foundayo (orforglipron), a once-daily pill taken without food or water restrictions, was associated with reduced body weight of up to 13% in adults 65 and older with obesity or overweight, in new analysis of ATTAIN-1/2 | Eli Lilly and Company
- Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting2026-05-21
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting | Eli Lilly and Company
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial2026-05-21
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company
- Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference
Similar companies
The largest companies sharing ELI LILLY & Co's SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is ELI LILLY & Co's market cap?
ELI LILLY & Co (LLY) has a market capitalization of $1.070 T as of 2026-06-11, ranking #10 among US-listed companies.
How much revenue does ELI LILLY & Co make?
ELI LILLY & Co reported revenue of $65.18B for fiscal year 2025, an increase of 44.7% year over year.
Is ELI LILLY & Co profitable?
Yes. ELI LILLY & Co reported net income of $20.64B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.